Dr. Thanaporn's primary interests are in repurposing old drugs for new indications and the use of novel therapeutics in heart failure. He is also interested in heart failure outcomes and clinical trial design. He is currently co-PI for EMERALD-HF, a precision medicine heart failure trial in China using spironolactone in patients with aldehyde dehydrogenase type 2 deficiency, a common hereditary disorder that interferes with the metabolism of alcohol.
- M.D., University of Michigan
- B.S.E., Bioengineering, University of Pennsylvania
- B.A., Biology, University of Pennsylvania